Viatris Inc. (VTRS)
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)
Viatris (VTRS) is upgraded to Strong Buy, underpinned by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales CAGR midpoint of 3.5%, exceeding consensus, with $450–550 million annual new product contributions and upside from branded assets. Key assets such as Selatogrel and Cenerimod, alongside upcoming launches (e.g., meloxicam), support reacceleration in growth and margin expansion.
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating
Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effexor and XULANE LO, while other assets will see their readout events in 2027. After Viatris Inc.'s 89% rally, the asymmetric value setup is gone, and while the stock is still cheap, it is not compensating for the associated risk in investing in VTRS stock now.
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPS
Beyond analysts' top-and-bottom-line estimates for Viatris (VTRS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Viatris Gears Up to Report Q1 Earnings: What's in the Cards?
VTRS gears up to report Q1 results as import alerts, regional pressures and growth in key brands shape expectations ahead of May 7 release.
Viatris (VTRS) Earnings Expected to Grow: Should You Buy?
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
